In this video, three people share what it feels like to take GLP-1 agonists for weight loss, including how quickly they noticed changes and the semaglutide side effects they experienced.
You can read about Pete’s weight loss to qualify for bariatric surgery, Larisa’s struggle with food noise, and Arelis’s experience taking semaglutide after weight-loss surgery here.
References
Centers for Disease Control and Prevention. (2023). Losing weight.
Friedrichsen, M., et al. (2021). The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity & Metabolism.
Garvey, W. T., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: The STEP 5 trial. Nature Medicine.
National Institute of Diabetes and Digestive and Kidney Disease. (2017). Choosing a safe & successful weight-loss program.
Smits, M. M., et al. (2021). Safety of semaglutide. Frontiers in Endocrinology.
Sodhi, M., et al. (2023). Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. Journal of the American Medical Association.
U.S. Food and Drug Administration. (2023). WEGOVY (semaglutide) injection, for subcutaenous use [package insert].
Why trust our experts?
